ELQ-300
ELQ-300 is an experimental antimalarial medication. It is the first entry in a new class of antimalarials known as 4-quinolone-3-diarylethers.
ELQ-300 acts as an inhibitor of the Coenzyme Q – [cytochrome c reductase|mitochondrial cytochrome bc1 complex] - A mechanism shared with some of the most potent fungicides known, the strobilurins. In preclinical studies with mice, ELQ-300 was found to be highly active against Plasmodium falciparum and Plasmodium vivax at all life cycle stages that play a role in the transmission of malaria, and to have good oral bioavailability.